BPC 157 for Acute Hamstring Muscle Strain Repair
Condition(s) studied
Investigational drug(s) / intervention(s)
Pentadecapeptide BPC 157: subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.
Placebo: subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.
Study summary
This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.
Eligibility
Primary outcome measure(s)
- Time to return to unrestricted sport participation (days) — 8 Weeks
defined as clearance by a blinded sports medicine clinician and completion of a standardized functional performance battery without pain-limited stopping. - Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), measured by blinded central radiology review. — 14 Days
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Peking University Shenzhen Hospital | Shenzhen | Guangdong | Recruiting |
More Hudson Biotech trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07437547 on ClinicalTrials.gov ↗ ← All trials in China